[Study on levels of serum phosphorus, bone alkaline phosphatase and 25-hydroxyvitamin D in preterm infants with very low birth weight].
To compare the levels of serum phosphorus, bone alkaline phosphatase and 25-hydroxyvitamin D3 in preterm infants with very low birth weight, and provide evidence for early screening, prevention of metabolic bone disease in preterm infants. A total of 110 newborns who met the inclusion criteria were selected in pediatric ward in our hospital. The case group included 60 preterm infants with very low birth weight and control group included 50 full term infants. Fasting blood were taken from the subjects at week 1, 4, and 12 respectively, and ELISA was conducted to quantitatively detect the serum levels of phosphorus, bone alkaline phosphatase and 25-hydroxyvitamin D. The increase of serum 25-hydroxyvitamin D₃in case group was smaller than that in control group; the levels of serum phosphorus had no significant difference between two groups. In case group, the level of bone alkaline phosphatase increased at week 1, 4, and 12, and the 25-hydroxyvitamin D₃level had significant difference at week 12 (P<0.05). The abnormal rate of 25-hydroxyvitamin D3 level was 26.7% for case group and 0% for control group. There were significant differences between case group and control group in levels of bone alkaline phosphatase and 25-hydroxyvitamin D₃, suggesting that detecting the serum levels of bone alkaline phosphatase and 25-hydroxyvitamin D3 would facilitate the early diagnosis of metabolic bone disease in preterm infants.